<SEC-DOCUMENT>0001193125-12-194827.txt : 20120430
<SEC-HEADER>0001193125-12-194827.hdr.sgml : 20120430
<ACCEPTANCE-DATETIME>20120430125115
ACCESSION NUMBER:		0001193125-12-194827
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20120430
DATE AS OF CHANGE:		20120430
EFFECTIVENESS DATE:		20120430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		12793522

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d344183ddefa14a.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Additional Materials</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>(Amendment No. &nbsp;&nbsp; )
</B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by the
Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a
Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only&nbsp;(as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167;240.14a-12</FONT></P></TD></TR>
<TR>
<TD HEIGHT="32" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>SANGAMO BIOSCIENCES, INC.</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Name of Registrant as Specified In Its Charter)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD COLSPAN="5" VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="32" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box):</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of each class of securities to which the transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate number of securities to which the transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per unit price or other underlying value of the transaction computed pursuant to Exchange Act Rule 0-11 (set forth the
amount on which the filing fee is calculated and state how it was determined):</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed maximum aggregate value of the transaction:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fee paid:</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount Previously Paid:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing Party:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date Filed:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px" align="left">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="middle" ROWSPAN="5">


<IMG SRC="g344183txlogo.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="5" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sangamo BioSciences, Inc.</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Point Richmond Tech Center</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">501 Canal Blvd.,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richmond, CA 94804</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">510-970-6000 <FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT> 510-236-8951(Fax)</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SANGAMO BIOSCIENCES NOMINATES SAIRA RAMASASTRY TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>THE COMPANY&#146;S BOARD OF DIRECTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Richmond, Calif. </B>&#150;
April&nbsp;30, 2012 &#150; Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in the development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene modification and regulation, announced today the nomination of Saira Ramasastry
to the Company&#146;s Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since April 2009, Ms.&nbsp;Ramasastry has served as Managing Partner of Life
Sciences Advisory, LLC, a company that she founded to provide strategic business advice for life science companies. From 1999 to 2009, Ms.&nbsp;Ramasastry was an investment banker with Merrill Lynch&nbsp;&amp; Company, Inc. where she helped
establish the biotechnology practice and was responsible for origination of mergers and acquisitions (M&amp;A), strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the M&amp;A group at
Wasserstein Perella&nbsp;&amp; Co., an investment banking firm. Ms.&nbsp;Ramasastry currently serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson&#146;s Research, the Board of Directors of the American Liver
Foundation and as a Special Advisor to the California Institute for Regenerative Medicine (CIRM). She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University as well as an
M. Phil. in Management Studies from the University of Cambridge. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I am delighted to welcome Saira Ramasastry to our
Board of Directors,&#148; said William Ringo, Chairman of Sangamo&#146;s board of directors. &#147;Saira&#146;s extensive experience in global healthcare investment banking and strategic advisory consulting will bring valuable financial, commercial
assessment and business development skills to our Board. In addition, in her capacity as a consultant to Sangamo, she has gained a thorough understanding of our technology and programs which will provide the Board with valuable insight in the
development of our novel ZFP Therapeutic&reg; platform.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I am very pleased to be nominated to Sangamo&#146;s board
of directors,&#148; commented Ms.&nbsp;Ramasastry. &#147;Sangamo has established an innovative platform based on their proprietary ZFP technology and is at an important stage in its development, having recently launched two Phase 2 trials in HIV and
established its first therapeutic development agreement with Shire. I look forward to contributing my healthcare industry experience to help position Sangamo for future growth and success.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Ramasastry will be eligible for election to the board at Sangamo&#146;s 2012 Annual Meeting when existing board members will
also be under consideration for re-election by shareholders. The meeting will be held at 9:00 am (PT) on Thursday, June&nbsp;21, 2012 at the company&#146;s headquarters in Richmond, California. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Important Additional Information Filed with the SEC </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release may be deemed to be solicitation material in respect of the solicitation of proxies from stockholders in connection with Sangamo&#146;s 2012 annual meeting of stockholders (the
&#147;Annual Meeting&#148;). Sangamo and its directors and certain executive officers are deemed participants in the solicitation of proxies from stockholders in connection with the Annual Meeting. On April&nbsp;25, 2012, Sangamo filed a definitive
proxy statement relating to the Annual Meeting and is mailing the Notice of Internet Availability of Proxy Materials to its security holders. The definitive proxy statement will contain important information regarding the participants in the
solicitation and proposals submitted to the stockholders for approval at the Annual Meeting, including the proposal to elect directors of Sangamo. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom">


<IMG SRC="g344183txlogo.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sangamo BioSciences, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Point Richmond Tech Center</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">501 Canal Blvd.,</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richmond, CA 94804</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">510-970-6000 <FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT> 510-236-8951(Fax)</FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stockholders of Sangamo are advised to read the definitive proxy statement prior to voting at the Annual Meeting. Stockholders of Sangamo may obtain, free of charge once they become available, copies of
the definitive proxy statement and other documents filed by Sangamo with the SEC at the internet website maintained by the SEC at www.sec.gov. These documents may also be obtained free of charge by calling investor relations at Sangamo at
(510)&nbsp;970-6000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Sangamo </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. It has ongoing Phase 2 and Phase 1/2 clinical trials to
evaluate the safety and efficacy of a novel ZFP Therapeutic&reg; for the treatment of HIV/AIDS. Sangamo&#146;s other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies such as sickle cell anemia and
beta-thalassemia, and a program in Parkinson&#146;s disease. Sangamo&#146;s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific
DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic
collaboration with Shire to develop therapeutics for hemophilia and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich
Corporation. For more information about Sangamo, visit the company&#146;s website at <U>www.sangamo.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>ZFP Therapeutic&reg; is a
registered trademark of Sangamo BioSciences, Inc. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press release contains forward-looking statements regarding
Sangamo&#146;s current expectations. These forward looking statements include, without limitation, references to the research and development of ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo&#146;s ZFP technology
platform, and election of directors. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include
the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further,
there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due
to risks and uncertainties that exist in the company&#146;s operations and business environments. These risks and uncertainties are described more fully in Sangamo&#146;s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with
the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Contact </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sangamo BioSciences, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Elizabeth Wolffe, Ph.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">510-970-6000 x271 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">ewolffe@sangamo.com </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g344183txlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g344183txlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`7@"B`P$1``(1`0,1`?_$`'H```("`P$!`0$`````
M``````D*``@%!PL&`0($`0$`````````````````````$```!@(`!0(%`@4#
M!`(#```!`@,$!08'"``1$@D*(1,Q02(4%5$6\($R(Q=A0B314C,88D,E)AD1
M`0````````````````````#_V@`,`P$``A$#$0`_`'\.`G`3@)P$X"L&RNZ^
MH^G,&C8=I-C<0X,8O&YW48VR%=8:%GYU!,YTU#UNJG<J6>RB11,Q1*P9N#=0
M<N7/@*.:@=\;1/?K8YSK9IZ_S-G&8AX*8LMPRC!8<M-?PS0X2+;K&:O;?;[L
M2LR4>%CDTBL(LJ<<L+UXH!2?0510@+S[J^8[:M=LYY8P!2.W=)Q]KP_?[=CJ
MRN\WYA4@I/\`,U.;>0RZYJ;5*,_!LU>"T!=$0F%2JHJ$.0PE$#"!3L/=\W(^
M,NU)(]TGN2XBQGA:"R9+($U&P9B&;L;[(F9XR58.PJ3>3/;G+QK%OKH]CG4B
MW<)E]AE66QI%9,WN)HF!-;+_`);7>`R#E5W?L:W[&N$,>LY(R\3AZL8EHUQK
M#:*,MR:1]FM-\@)ZY3CQ5$H$7<HO8XBJ@F,BBW`0(4+]T/RT=T]L\I=OK7Z-
MQK1,&6";VRP'%;)9$QV_DGY<Q4YWD^J1+JE5JLV)%^?'5=M,>]<%FT_OY-RZ
M^A-NX:HBJFH!W/(%[Z^T_9\S9KC5,48)PED_%^:<=6JR/9G([B\I6,;94+0A
M%SD%%+5FP1$=',&4+,1:Y5%D'BBJKH_,"E3`#!0K7+S:L"V!>,BMK--LE8S,
MLN1"0MV%+Q!91B$"'$"_?*56VL<=3#5NEZB=-%Z_5Z?Z0./H(,RT[O`]NFV:
MOXKW&DME*KC+7_,UOD<?4*Z9DCY_%9)6\0_Y(9>MBSN$7&KD7C2Q#DRCHO7'
M"1$QR.#D^K@+XXVRIC#,M48WO$.1J+E.DRA0-'6['5M@;I6GH&(53DVFZZ_D
M8Y8P$.`B4%!$.?J'`>]X"<!.`G`3@)P$X"<!.`"?W-._EH%VPVTG5LBWLV7M
M@F[906&NN'WD9/W9H[Y&*W#($L+G]OXR8F4*`G_)JA(F2'W&[)P`<N`6H[<?
MD#=SKNS]W[6G#E+6I&`-8"6*V7/(V':178FR_D<3TVHS,M,ER!D:VQCRSRTJ
M^<)M62"\66$;$?.T3%;`("(A7WS;8['+;;K360B(5HURI)Z]V_\`?4\DH?[J
M6I;+(2B&-X]XCUBD!8>4/8S)'`H',#H0,(@4H%!G7Q?];\88)[/^N%RI$(S0
MN6QC>SYBRQ:?M422]GLCFWV*N0C-Z\!,'"D94ZM"-6#-`3"BD)5EBE!1PJ8X
M*I>6'J)5''>.UA<U)NA!R>ZF/</Q5W69HI)&=7AKDQ[AS]RJE*4I3NUZDA#H
MG$0$3F9=0B(F'@,7YBV0U*QL[ICI!2BK0>%=9M3ZU*4^IME#(Q+25M\],4EN
M<K1/I04-%4G%D2U0.("*13*E+R`YN8/9:,]O75?7W0C$6K$1A3&TK0IC"M4C
M,KM)>HP<F;+-ALM59KWJR7QRZ9*.+')666D'*HG<'/\`;I'(BA[:*21"!R]>
MUWJHRR'W[L!Z[T]!TO4<8[OV.<*9,YW!DJ#K;=K)D!8SER<1.*;B#QX5`RIA
MYF.L'^XP<`RYY+=);]P/O/=JSMLP3[VEG,(C(9`D6H`9Q7JWF/(";JX.`$HB
M<7T%C+#[B333'I`P+)^H=7,`7O[>^O&MFWOD35[!]IQ?6H'6:>VZV&DHC"\6
MV(SIQ:7BEME"[4''+B/,?H7K3LU+CV3YKSZ734RJ0AR4$.`;S\Q>,QE5.TQB
M6M(UFMQ#QAM;BV$Q9&Q<8QBV]7;L,=Y14E6M<CV"+=O&1A*XS,V,BB0J)2&(
M'2'(G(/#^'9H95,8Z9S&^,L[N0Y.V-M&0Z-`QX6R=:T)#$-(LD-`(+K41N]3
MKDI:W-^I\H8DLZ06>-F?)!N=%-5P"P`WG/*&[J^C.Y6R^&\@W3&.V>.,6;&Y
MHH"%>RA18>O2*<+4LB6*O-$:Q=<9MJC+1Q2-8XGV_P!^G+(HE#E[1@X!Y[M*
M=RV8[G^N[C-\YJAF[5=U'N85NBTRA%N5:'D:/FXD91M;L+7YW%5U2_U$I4Q*
MLY_'-2H'43*!E0.!^`*B("'Q#@/G`3@)P$X"INW.]>HNA]%:9%VWSS1<)UJ4
M<+,X$EE>.GEEM+QNE[SAG4*5`-)>XVQPU3$#+%CV+GV"F`R@D*(#P"U_D`[@
M[[9[[>M&VB[/N6XFTZ'RU0N5CV5S;@FPNXC.C.(C),()PQ;(O$HFXTZCUE)%
MY^Y/QJ;>?9*D.#TK9DBL*@(K=I7MQW_NQ;MU?7>/L,M`UQ6.L&4<XY,!$TQ*
M5?'=?6;'GI9$SWWDWUIM$]*LXI@+@3E&0D2++`=)-7@"_>(?+Q..N\G9Z'9V
M9&]AL6N>=\?0*;WH^[8V:NV2DVB2;)]12&^[_`TN1(?I`!Z2G].7`>P\T120
M-W0L,IN?=^Q3TMQU^-`P""72?+F;Q=BE_M$PN`Y&'X^@<_EP#2GB8;,Q6=.T
M9C_&AI%!>WZLY&R'AZPQ_6`/4(68GW63J3(J(<Q,#%S"7<S)%3D!5%(U8H>I
M#<`#[R\[:3&O<S[7^3W)NAI2*5#6Q4PE^DI*9L`VL#@PF]0-R23`1#EZ?SX"
MLWFH8T4C-ZM6,WLB">`RUJLWKK-\F`BW=RN-\BVM^]%-<!%,YBPN1(P>11]"
MF*/SX#H$=OS+T5GW1K3_`#-#N`<L\C:VX:LRAP,!S(R;R@P833)40$?^1'S*
M2[=4/B"B9@^7`((>*S16E^[YFW^2I-(JCG'6,=E++&&/U&.WG;GF^I50RY1,
M',##"3<@F(CZ\E/]1X"[^8["E3/-?P](7Q0!B9^K5.O4E5R(>RV5M6FUFK%?
M3;=9A*'W%S<.$2<N7]]8>0=7`+1[/RM\[07?QR?D&/BW2SW77=21S'`1:Q#-
M1MF)KU9!R`PB4U3B0OLVW%-T%@94HB4IES^O,H@`-K^7NQ3V6[4^H6UV&Y,+
M;AJ.S/2,A*3$?S4:KT;-V+IE&D6U<"&,1%M^0<,V0]7U$7DR$]!$0X"TWA^;
M&P.6NU23"B<BF>WZN9IR!4)F(.<HNFU7R3*N,J5&9]L!$Q6$I(6.7:)&$`ZE
MHU8/]O`<U;;*0D3[F[+2ESCE@EC;.9D?VJ)>@<K@'XY4L;B;C713_654''NI
M'`?4!Y\!U`O(FJE]S/V([;<=3YF6@*K4(#!.<W$5C]\Y@4YS7F(9L'4G%-$X
M11L0:S7Z]-LYM5L400!I#B/(0(`<`@GV^?($[E';UGH1K4,VSV:L-,ED4Y7`
MN>):6O\`1W,6"J8K-:O*R;Q:V8[=@D4WLJ0[UNV*H(&7;."@*8ATS^TWWD-6
M.[9BEW9\0/E:+F:ELF:F7]>;9(M%;Q15')BH$G8EPD1LE=<?/WAO;:S31(A2
MG,5%VBT<F!#@"W<!.`#IWF>\-ACM%:\)7FR-660-@,DDE8?7W"!7XM7%NG&"
M*02%LM:[<1>0V-:>H\0/(N2`"[I95)FVY*K>XB'.FV9[=G?][C:=P[B.P&L&
M>LFM++%&M+5U+%KL#,Q%"]A64C(K%N!9"Q,L@1U$BXTX'8LXR$.*R9O?_OJJ
MJ+*`?7PS\V,<G8;[@';QR.*LG6WC./RG#5:4.91NK7,D04AB+,D9]DX`1;M3
M"P@`53`H%%1V<3!U"/,-.^&HA7<9[\]P["\N=$E[B\5LHZ$*Y`B;]6&QGF)S
M7;DDB4_)4.4C-11UB!\R%$?Z>`&QG])QV9/)N7R"\06@L9UW;:/S`T<%4%%H
MIKWLR=P[MY6*@`4BS6NU'(<Q&\A^D',:8@_TB/`%\\VC6>1?%TKW3K[8'];(
MRMVNUSEFI/>;MG#Q4V3,7*&=H@9(S>5;&LH$,(]/-$H`/U<`OSX]O=G7[5VY
MK5_D1X_/JQL(C"X]V`8(@LL%;;MW[G]F9?CV21%%';W'$I(N/NDTRG4<0SQ\
MFF0[CV.D#O>;)24K*IVYMDJH^C[%0K14<PTIG:(1XA)0T@D]/CR^TU_'2;11
M5F^C[!"R;UPT62,8BR2(G*(E$!X#*=]1)COOXY7;+[@$7[+^V8;3QE`WE^GR
M<*-B7"K&PQEA`ZY>LZ?3FC'T47I.(?'U^KEP!8O$#VP+G3M?.,%R\D=W;M0\
ML6:@@W75!5R7'.0UW&2:*\$>?65J65EYR-0*/]*<8!0]```"F':4[:NY_;L\
MB+:Q9[B&Y+ZAYFQ_L'.UO.+*)<.L82-$N>0ZWD7'$.XLZ9!C6.0829;(Q+J)
M5,F_`R;A=-([,2+F"LGE?0TWJ)W2NVEW&ZFU=-3MF-7!^^9!T@ZM&LF6HZ\@
MV<*%Y`*\S5,@(M.@P\E4&QB_`IN`P'F7Z@PTXIJ7W-,9,TWE8R=6H_!^2YE@
MB;[=ZL>*>Y$PC9G)TP$IU9JL.9IB=8_+^U'LTP$?I#@+?>.W<*OW7NQQM/VN
MLS2:;V9P\RL&*8)^^.1V]@Z!E)&4OF#+:D0Y154<8XRG#R(-`Y&*BWB6B?PY
M!P"[WCL[N67M:=U];!N;'2E3QUFRV/\`4W/T5(+^U'T_(T/;G<'0K<^%0"))
M&IN2$E(YRX4$I&\5+/E!^`<!KWR?M276J_=VSW*,HLS"C;,-X396E+D;@BU<
MKWY-=ED1-,Y/[1G"64X*:4.4.1BIKI"(?6`B#W7CDYJ@MXNR)AO'^1R)6A.@
MUC(^G.3XMXM]R61K%81<04%$/`4ZS@DZPW:(=`P&Y\PY_+@$M^ROJ?@'&O?>
MR_VZMT\54O+%/FV6U&K3*#R1#MI)BI:*NJYGJU:(9PH5-Q"3\Y5Z&X"+DV1V
M[U$TB0S95,YBCP'CNY-I=L[XVW<IQUG/5:Z69EBJ<F)*]ZR9*D!4>MIJLMG+
M9.^8!RPDW%LRL:L.SD$V$HW4`B<O#O&SP@(KG.5L'2J[:N^^,.Y7IYBG:_&!
M21B=P8*P]_I9W)73_&^4Z^5%K=Z+(J\B'5"+D%"KL5SD3%[%.FKH"%*N!0"^
M/`<N[<+:>J9W\K:HRVV[QBO@7`VYV/-?H2#MX$/3:E3\73J4#7EY1I(=;%*N
M264U3S\H9<HH'*]6,KS2#D`=1(>8#_KSX!/7!&JQ=+/+.R0XQQ`IUO$VZ>EV
M2,X)Q<4T(U@V\W(3U6-D=J@DW33;H*+95H*DLHF``"0S)`#D!BAP`1\GB\[)
MOE6,+TX4-"8+V$R\2YNG`%,C&+X3W&>OXFXF6(8"%_'8TRC(/UB$`1`!KZ1O
MF`<!>_S7-,@D*OJSOO6(D3.J](2.M.67S9L43&AYC\I?,2R+U5,`,1M'RC>Q
M,S*GY@*C]LF`A]("%_-?V*/?6\88F,Y`Q+#G6GX;?8R9N7(@YE&^QFJGVSK&
M[]=P0QE4Y#(<##0YGBO+K,VL"X"`]0\P3[[9_;R9]U/0W<;`N/HU)CO-I=98
MO87`+15)-G(98QG>HQU6LLX'ECK&1.11I9J1'/X%1<.EC.RIT3&20D'1RAK'
M_P![I[._9]RAVU]CEGI\D:6Y6HV=]3IBT@Y0LK&G,IV1Q;F/`#X)+VWK=6E,
MLB'FXIJ<!428,WS40(DQ:)`!Z^SFNON;XPG=.T_?)A+3N`5<J7:D,#_\A1%H
M%4@]@Z6U:)&$PHJN,E4*8$@EY!UK#R]>?`4]\-795?%_<@R/KR^>^U7MH,$S
MR+)D=8Q".,@X==A>JZL1,1Z%%4:8O92_#JY*?Z<!T_\`G\OEP"F?F.X-9Y%[
M6M6RZFASFM>MC:!/E=@3J.2LY$CIS',TSZOB1)U.S,.J;Y<VQ>`QT[41[DOB
M/UT91,+#=*CI,PM4$]-_>D/W[IE(/&GO(J#S/^3F6>*'3)4>?4<KY0H_U#P"
MY'AKYMD*#W0+UB(7!@@\]ZV7F-69=8@FK9<<35=O4$]Z.?(ZS.$9S"1?F!7)
MN`HCY,&#F^`>\]MDC!I!'Q.3Y2CYXA_M2`U$CW)E,A)NT.TQ1Z.E5:_)2JO6
M'(PF'F/KSX"\7?1SO%;[=I7LN[WS$BF^S,E%YDUFS&Z$1^]EKCCYI5&4U)R'
M6)E"JR,O3UIE,O,2E3GP$/ZN`*_X0>9#/<<[YZ^NG1NFN73#^8X-D90PE']X
MPEKI5G<))#])>@:1$E.(?'J+^G`4([X$(II/Y/NN&QE63_"M\DWG3O8-Z=#^
MT@Y%.VLL2WX@]/2'1.,\>NQ=!_O%V<1_J'@'%/($T=A-[.UYL?20AD)#)>(*
MM)["X7?@BD:1C[WBB*D9UW%QRIDSJ%&ZTTLI"'(`@4PORG'ZDR"`)]^&+NI)
MXXVYS-H_8998:1L?0G62Z)&+K`9LQR_B5M]S)A'('$`17M6,W+X[PQ/J5"!:
M@(<B!R#I4<!SO_*9[%>:G><KAW*]2L?S.3*%DEDQD]FL>TR/=3%PQ]=H**;1
M3C*L9769%G\U1K5#QJ"LN9HFJO%R:2SI8HMG)E&P4%[9WEA;JZ6UNE85V0K4
M;M[@FH(1M?C'MEE7=?SU4JK'E(T0BXC(@@_86YM#LB@5LA/,G#LQ4RH_?HI`
M7H#H>Z);HZ7]S'&M6W`UH>5BY2L+&RU`D'\_7(ACFG#;F=-#S-HQA:BJ%=SE
M6+)N(MBZ61;.5(N6*W0<H*N$BIJ<`FCYO^/V$=DOM[Y>:`1&<GJ5G?'[YPG]
M#HS&DV#'%F@O[A0`_2U=WI^)/7Z3*#R^/`%^[@&X_;UWQ[&5]P]<=W]1W.=;
MEIAC_)<74)7/^,$;LWV`Q_1JSD^*KAH-:R_FF=K?WNO&B56ID0<^XY41,7F8
MP<`*3PB=BGQ9?=[4V1=F4C5HW'FPU08F5-TM7S1TZQSD%PDB)NCF_;O*V!A*
M`#_Q@Y\_3D'A-26"?;*\O/+.#8A)2#Q;M)9\A5R/CFI^B/+7MC*4QS[2&#9`
M`*F#2%R>R:1B)>7]DB1B@/+GS"FWEU=N.-U:W4K.W^,:^2(Q1N>VF9:W-8YM
M[,7`["58&G[\,!4S"DT+D:&D&<X4H@4SB2_**`'(.0!:OPO9@EC?]S[!TJ8%
MZ_>\)8LF'C%4>I$Y&RV5*A)&]L>8<EF5Q*0_(/J`"@/P#@%[^Q+;WF->\SH)
M)1SE1N=;9."HBJB2HIBI'7]"7QW((G.(AU).&%C4(8H_U%-R^?`._P";_,,U
M`P'F;)N$KYIKN3#VS%5XLM"LS*:CL4P4LWF*Q*.HIV*T(_R!]PU376;>XEUJ
M<S(G*<.8"',-M=]K9**VJ\;',&QJF+LDX88YMA=>K35L=9CC(F&R'$,I/8W'
M*T`\F(V%EYM@W3L4"S"38]+@5%(YVB=0B9S&3*"S/;9\E:CZ0=L>&T`M>F][
MS`K&P&<JVMD"*RI&5R#>1>7K'<YPZ(03FA3KE$D22VG25+]R8%1(8P=/5R`*
MB>*0R?N^]EK>JRZP184?8![(])>H/L/\+71IR4'TZ""\=HAS_P"[D'SX"SGF
M81K)GW6Z`\;$*5S+:=8H=R)@Z>9W#?(>8HY$QN7KU`R9IAZ^O(`^7`+B6+9>
MUV'47%FH[GWAJ&,,\YASG'+*+`=,\IE:DXDIZD>@D/U()1A<:KK_`/:8\B<?
MCSY@TWX4%O5CM_=HZ1[@@WM6I#N?.EU"!3N:?EO'+5NH)?F=)&V+``_(##^O
M`;`\PQPD3NF:(`P`OYAO@*B+&$@C[P]6P%Y&-`>7(0`%DE.CU^(CP'1EE8]K
M,UZ2BY1%-RRE8-Y'R+=<H'2<-7T<HW=HK%-Z'3525,4P#\0'@.-WV4IJ3QAW
MN=(@J1ECG:[:,*$3[=3H.M7+4^FZ!-E$P<BF14K<TXZP^`DY\!V7^D/]?Z^G
M^7_7@-";![1ZY:G4YKD+9?.&,<%4Q])I0L;8LGW"&J3"5F%B"H2*B!EG2"LM
M(^R45#(MRJJ%2*)S`!`$0`$?<?[`/;G[NN*EMA-;W6-,39TO4&XM6.]F\$&A
MY'%^5W:Z1@9*9-@:BN-7O$3)/&_M.)IB5*>;'`QA7<`D9JH"8/9?S;L=V7.]
MA7=7<Z-'])99!RI"ZH;*T%5\=S79%.[RC6-QGD.-7()6,BS@K'.QLW$RQ""*
M\$]<%3$J;Q0.`*WYPEU1=94[?..2*D%S`X^SW=7*('#K30MEDQO!,E3I_$"+
M'I;@"F'XB0W+X#P!8--/%S[3.3M.=3\@YDP-?E<O7C73#%VRC*1V<\L0R4C?
M+5CJO3]L<?B&MG+%Q:*DT_6$K=LBBFB7D0H``<`OAXD;5&F=ZK/]-K`J_MAK
MKQL-640]]1<!@H#+V,1AQ664.8ZX@,:AR.83&,(\Q'U$>`N[W=@"O^6SVV96
M%1#\C+/=*SR7M``G5.YRO=:ZX65`A1,)B0:)"B(\_H('R#@#@>6)B:LY'[,F
M;[7-MFAYK"62,)Y,IKU=-,5V4T_R/"XPD2M5C!UIB]K&1'R1B@/(_,.8#R#D
M"XGA;1CF/RQW&\D*D.6#J.M]%C'[@0$$".9>RVN>;D.?^DI_M*<X,'^@#P`$
M>Q13'F2>\QH-$,$#N3(;*05Y6*D7JZ8['R,OD.17-R#D5-!A6U#B/R`.`(3Y
M94)0X[O764]<C&GWT]A_7V5R6UCTTTUI*W+1;J.ZW94B@(R+NC,(<@F,'68O
M0(\^?`-&^7YDZ(QQVA\>XL8%2CE<O[!X=J4;#(@"14J[1*K:;XZ*FB7D`-8U
MW6XY+E\"BH0.`MWV2:O4-=?'MU\O%CAX5)K"ZR9MSS8G\A',51.QGIO)N3CO
M':SA`XJ)A".T@#JYA[12E^``'`*>>&-AMS>^Y%G'-J[81B,+:TV)L1<"")&]
MJRM=*S"PZ/6`=)#+5V%FN7P$0(/+TY\!KSR(J9=^X+Y"%GU?PQ[$O;JUC[%^
M((XRXJFCX\]4Q5(9JN[MR*!55"MJZPL$@HXZ0Y@9L<OQ#@`']O/2RX[^;6X^
MULJ2[N)0G6MIM=YM#=J5T6F8ZH%;D[;<K&N1400*HC&Q8M6@*#TJR#INEZBH
M`"#'/A85]T[[E&PU@3((LX#36WL'!^D#`1Q-YBPW]H43\@Z1.G%*_#X\N`S_
M`)(\HKF_R+M7,-M1"0&ML-+L1_8I""ADWEWRJ\N*S8Y0$>2BS?(2)A#X])@X
M#H?;9YL@-;=8-AL_6=ZA'P>&\,Y(R(\7<&*0AS56IRLJR9)@/+W'4B^;)-T4
MP^I194I`YB(<!RPO%PU\FMB^\M@VVK,W#ROX!B,C;#W5\1(YT6IX:`>5FJG7
M7Y"FDJXR)=8H2`80,<I#B'](\@ZWW`<Y'S;*;FA/9C3C(,DG,.->G.$;+3Z<
MN0'"E>B<OL[Q*3.06RXEYM6<Y.U!Y73I]?2HZ;L#='4#=3H!D'Q=]6;;K!VL
MJ2:>S[2<[5O.]XFL\X\'&\I+35,QK5[=`5F*=4!K(3;")?IV5C9J^_7GF8-&
MZ4?-+N6_2=4BRR@+'=PROQ.^_EPXBQ%C%B1VWQOF'6JJ9#EX]'J^]+KW!1>5
M\M2;M1(!_OUV%B7D0)U!]%8XI/T#@-3>0<]?=Q'R+L8:?5APM*1]7EM9M24O
MLS"9)FO;IIM>LA/RB7J`AX)3)[LCH_+F0(XW/^C@.BUM3E2OZGZ=;`9A1*VA
MZ_K_`*\Y%N,2U(4I6[9''U!E'D!&-T_Z1]Q>.;MTB?[C&*4/CP"!'A2XV?VS
M=[<3.K])5V2C:Z1M-<2*I3'Y3V7LFP\ZF8RH_2#ARSQB\$?7J$.?R$>`L]GY
MZUV0\TC!M4CQ"088%''K)XH4"J)-G6+-;K%F5T'4'H065DFP2$1]2K@)?CRX
M`P'EU9")2^S?>:X+H$%\L9XP=0T4NOI,[".GW^27"(!_O`J-`$XA_P#'G\N`
M#%XX,:EK%V(^[UNE,)%8'LD1EJ%K[PY036D$L.X#?A7B(K#RZDW-XR@NU3#G
M_P"8I@^/`4;\-C6D<B=PG+&T$V@1*GZIX*FC(R[DA2,V5^S$JO4H;W'2P`B@
M5.A1EG4.;J`Q`*41Y%$>`'#/VJ7[PWD$L9R)]V6@-D=XJU'P74*KH&>!*!98
MZ,CG9R?)*(PC10=+`7D3FF<?0!X`]'FS9H>63,.AVI]?.+MU!TW(68)*%:?W
M'#N3R+9(;'M'(*!0YBL4E%E2(A\1^X'@#/\`>UR(V[:?CI,=?HE9&(M]EP9@
M?1VL-D7`(J+.Y>FQ<1DU5/VQ*JL93'E4L)SG+\552B8?J]0KIX8FMI<::`YQ
MV8F&B;64V/SDO$Q+Q1("&7QY@^'-!,%P7.`#['[WLEB(8`'IYH`/QX`=_CW0
M;;=SO-]V;N*V5(LM$T:,S<]I+M4I56D<_P`_7>T0U34;N5`$"A&X?I4G'D`!
M#_CN1Y^G`?/%HU?C,/Z2=SWN>W5@FW7)BG,.'\82+I),IF5-QI0G^2\JRS%0
MQ1,+6<L`PK(%"B')2&7)\QX#^WP?L6N7-TW_`,W.$#E:QM8P?BR,=B7Z5G,_
M+WNVSS<AOF=!.NQQCA^BI>`J#AU`>XCY?<Y;8T0G*?C?;JW7)60,;WF:53TV
MJRD!6I!,Q>LHLY&QXTC$T!#Z1,[)^O`%A\OONLU2A830[86([&A*94RZXK5P
MV26BG9%"T#%D+(,K/4J'**-U.IO9\B3[%G(*MA$%$(1D`K$]N10,(7C\5KM:
M3>BFF4KL/F2N+0.P^XR==MKJ#E6AVTWC["<0@Y<XTJ<BW<)E<1LW9#2KB>DD
M!Z#D([9-UR%7:'``:7X"H&]>C^!NX=K5?-7MAZ^:7I-R;INHN:C_`+=&TT"Y
M1Q%AK=_I4DX17+%V>O.5S"F82F1<MU%FK@BK9=9(X(+8GS'W)/$PV6D\19OI
MLSL?VY\NV]9[!S$,+QK3+,("3W;IBJ8>G=Q^,LVM(5,OYJKR*A6\H5`.9U$2
MM91,-R^*F%9VW[Q7<=WCDV<@>24@\EWRD,["9NK-0JVR>;7DP=X].V5<-2S$
M;5(E>.5%$YD@*\5*01*(#P%9^U#!GV$\LS,5WNIQDG5*V4WMR:F5;FJ0'=5/
MDRJ59,ON")@3A3RK0R'K]'VQ/TX!P/R6KZIC[LG[MO6[L6CRS5S&E!;B4XD.
MY2NV9<>P$HT((<N?W$([=`</FF!@X`2_A08E1KVCFU.:%6Y$W^4-F6-(3<"D
M!5EX7%6.:](,^2WQ40)+9*?%`/@4Y3<`/'LOSRVQOE;;SYF<\G*56E]V+!%K
M'_J0BHN_1>&ZYT`;F("E7I=)+T^`?#TX"X/F[Y5"+UUT:PBDY$#W?,N3LH.V
MI1]#(XSI4156:JA>?J'NY45`O/Y@/+Y\!IW8=,=$/#=POCLW*$NNWA,=F<%<
M#]N_D!SUE&3SZ]*"(\E%#&Q%6B-#<P]$`#GP&Q.TCC=[H'XM>[VW0-%(G)>R
MV-<_9$AY,_\`9?LX52'=X`P^`&Y`8&[>9*[F6OK]193J#^H.`&CX86M<7DK?
MS-^QLVT*Z1UGP89C5Q.D!@8WO-<LM5VDFFJ8!Z%4*-7[`VY!R$0><^?IZADN
MYX\3W4\M##V&E.<E6,?[`Z@X;5;..:R!J[0&U2R9D%F"0\RE1_(R\R4Q>72)
MN8C\1X"V?F^YMD5+/HAKBT<"G$,X'+6;IUH!C<G<E)R->HE3<JI\^D1CVL3,
ME3'ES_Y1^`9!TAKK33CQW\6/8LA8MQCWMLV?-KP[<OL'3M5NQ!9,TSCHQB\C
M`X-9+(L8Q_4>KUX`,WA4XU04TFW=O3EJF8V1-@X;'JSE0/5TSIF*F$C]NH?D
M)O;26R4J/P_^P1]>`OKNU@NM]H;QE<\ZXQ=@CY"4J.N4MB>:M$:B=FE<<F[(
MWU&NW>68D<$1>*MW\SDA\*'NE!4K!$@&*4""``/_`,;.W5W0;Q^MR-Z[29!J
M*U\SSE6/57)R_*CC"@UJ@4"N$$?_`"KS.1H]PS0+\!6>@'SX!(?1CN1;.Z!9
MOR=L#KLO3U\XY<QY<,9+7>[5+][3-;'(5E@+)-6JF,'#U&.3NZ\I`I$26>-W
M[82+*D.V4Z_0&\>P_P"/%F3-^7XWN<]V2+LLO)3EE_RQC?"&6_NY*_Y1N\B\
M":9Y:SZPFA.^CX-N^,5W'UY\0'<DN!%'R2+),K9Z#_W`3@)P&K\RX3Q'L1C>
MS8?SICBH97QA<61F%EI%XA&<]`R:`\Q24.T>)J?;/V:G)1LZ1%-RU6*51%0B
MA2F``<Z5=B^G]J+;3..U6B=SG[#C#*F#KI4I33C(SU$3+W-@]AK?CAM0\Y/7
M*CF#B0L4,O'#^>CI-5HTDU%#NUQ(`<`GSVRYC8;2/R6J%;=VL#6C6.T;59OS
MU`O:I:DU5:^W?[+&MO[30I-V*G^`OU=2R'/Q4>E*1ZZK=?K`1$IA$@`SOYA.
M2("H]I$]'?3D>RL.5]C,104#!*NTB2<VUK'[@NTTNR8]?W#EG$D@$#.%0**:
M)U4BF$#*)@8/QX=3YBZ[1+MLU4(=S&[79F;21"B7J2=+0&.'R)5.GU`QF#I$
MP<_7I$/ERX`%/C)NVE9\A'?JLR+@!D7]'W$@6`J&`5'3Z'V=Q_(.P*81$3'%
ME%+*#RYB(%$>`V%YG\=,Y`W*[<.*&:ARIV#'-QCHD/J$A9F^95K=;54`@>@G
MY1;7G\^0!P&0\PJSOXV2[8/;@Q<T_P#Q-9I+BR1M>:B"97\D[7KN"\2,B()@
M"28Q[6OS"*?(/@\$`Y!\08@[LVLJ&$?'-V"UAHK<@L\#::XTJJ(,4Q`KN/PP
M\Q](V63,!>1C'?,ZP\=K&'U.8YC&]1'@`2>#H]@0BNXW'`HB6SF?ZRO5$A$`
M<*0)$,VH(J$*(\S(H2!U`,(?`RA>?Q#@*B04*UI7FEN&=AZ12D=KK#-,C..1
M@^ZO6M,E.UWIZA#D8KR=0*G^A@+R^7`8SS8V#Q+?75.24]S[!]J2FU:"/5[7
MW,?EW(AWI4Q$1+[@$?HB8``!Y"7G\N`;SQ:+W97QT:U&U1/WIK)O:16J$6V0
M$PBI9%-7754.R2]D0-UC.-#I``"`\_0?7@`Y^$]F"L36E.UV"$GC0MTQYLJT
MR=(1OOI@_4JN4<;U2N0TB#83`J=J27Q=((F.4!*0W2!A`3%YAY7S/=PV$3@K
M6[M^TI\>5R1F;(C/-EYK4015[+MZ%2DY6LT"-<L&P'<*FO&0)E95DF4ICJJU
MX_(/4O,-J]CGMQ[1Y^[,.7>W3W+\&3^#=9,C2S:SX)EXRS#2MCS1U@NC?*3]
MQ8Z0^B99*L,X&^Q#61BSS*1'3Y%VLU=1PM2)*J`5'M\>.QVSNW79F&2L?XSG
M,T9HB5DG,%EW862B;Y8:DZ2!8"NZ17V$%7Z+5)$OO?1(-XL91/ER*Z`HB`@=
M+@)P$X"<!.`G`>"O>*L7Y2+6RY,QQ1,AA3;)%7&H?O>IP-I-5+=!/6TE"VBM
MGFV#T\%88E^S26;O&HI.$5$RF*<!`.`7O[P?C;8([J>19385GGS+6$]B'%>C
M8)N^>NCY-PV[0@HIK%Q2!\;3#^,?U,%4&"0.3P4HQ;JJB=RJU6<'4.H&E>PE
MV].X)V80W5PSL37:WF35^4KHY_Q+=\#SW[LF9[)]-COPMDI4)C642A+Z2W9(
MIK>.^W;&8G:B\AB(INCG6`1!,?M-;87#5GOV8BSGFRL67$:V7]C;]4,M5>_0
MLI5Y>LQ>SLI8:ZJ-BC9MK'OX]"M66WLGZQE4B@4K$3"'(.`,]YD6=J=4]\NW
MN%3E8B=RCK_1);)-NK*:X*+1#:0R95K'C]E.'2`_V9YLU/?JE1-_=*V,142]
M"J8F#)>1U:([.CCM'=]W7^&=Y*UP+%8^CKB#,IUCTZQ4W)Z>5JS3[B)$E$(9
M^_FU;#77AU>E%O+Q(MS")UD0.#"?<4[NG;WS9V6]O<R8OV4Q5;H_,NKN1L;T
M^@FML$TRF7(N6Z4^IT%1YK&CA[^[HFUP\M/E4>MU&G)N@U5<]8MR>\()*^*O
MO%%:>]T&I4*]2A8C&FXE8/KY)O'0@1BPR!)S3&6P_++&,8A0^[ND?^"*ISZ$
MOS9SF$"D,(!A>X9NU!XA\F?*FXC`3RU7P!O#CL)Y*-YK+R,!@E.EXUR$Q8\A
M$%73EE49)!,`^D3B`?#@"Q>9_)T_+M[[8=NQ2Y+?'N2<.Y@L%7=55NYEU;10
M['*XIFJ)*13=F@HY>-)<)1TJUZ2B8X'-R#X\`8KQL<Z;P/NUK>M<,JZ7Y>K5
MRUEHUT:ZOVC+T!(8GH6Q$+:"VNP5#&WYJYL(Y]&R%<M+L8UQ)$:.(PL*Y:G]
MSW452G"I?9R\8'<;2S-M1VHR[O6\P+<&;R/>63#.K(.)U&Z5Q.;9S4ACG)UY
MM[9G5I2L2@LBI/&*,%*)!S!1N[(L1-8H-UEU#UB_]A9?;%Q@['<GLE,PL!7%
MLS3D`VG[U&P58:F9PL76)::^_-3VC9`YO<+%%9BY,83K"H;UX"QO`3@)P$X"
M<!^^1/U'^/Y<!.1/U'^/Y<!.1/U'^/Y<!.1/U'^/Y<!.1/U'^/Y<!.1/U'^/
MY<!3;;#_`/GY]I`?^[@ZE"C^2BOVE_[*_P")/N_S'Y-K^&_:O^10^_\`RGY7
MV?M_LO[WO=/3Z\``'NZ1_BX2>SN16G<NG*O7MNCMZ5_D:3JZ.VZ^144/V/7_
M`-DC.)X*AYROC_\`HOX[V?=;F'[;V^OZN`(+HW']E^+[3-S9Z[3M1L7:P2_R
MR.0I7/2.3D*0X2/-B?(I;"GL/#P5N*V1GS$*TZ6Q"B^!/[$3..D1!6*G87\*
MB+SFUOP[<9HL<2O94'##"5QK6V:&#&3I1^46S)U+%UC@;L>M(+B4%!D[<JS%
MN`^^H9'KY@R7M2AX\"UV[:1LY/=:FMA0M-<6[>">*"6PU;>J_N:L$K35N.`6
MCFI$QX-V/&G;C:C)07Y,BG(_7]X40HVT2\05/9[-HVYSJZOL&IF6_GRZ780N
M?PK:&5AN,K^_$D?\X((XF%`+;]UUC'">-Y\_9'VN7`-05(,$?:XR_8HXG^S_
M`&)%_P"'/VM^S_9_QE^/COPW^-?Q8<OV-^+^T^W_`!G_``/8]KH^GHX#;(@7
MYB;^?/\`Z<!\Y$_4?X_EP$Y$_4?X_EP$Y$_4?X_EP$Y$_4?X_EP$Y$_4?X_E
3P$Y$_4?X_EP$Y$_4?X_EP'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
